303 related articles for article (PubMed ID: 23570584)
41. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
Tauro S; Cochrane L; Lauritzsen GF; Baker L; Delabie J; Roberts C; Mahendra P; Holte H
Am J Hematol; 2010 Apr; 85(4):261-3. PubMed ID: 20201088
[TBL] [Abstract][Full Text] [Related]
42. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
43. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
44. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
Ahmad N; Zaidi A; Badar F; Maaz AU; Akram MS
Asia Pac J Clin Oncol; 2010 Mar; 6(1):49-56. PubMed ID: 20398038
[TBL] [Abstract][Full Text] [Related]
45. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
Reiter A; Klapper W
Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
[TBL] [Abstract][Full Text] [Related]
46. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
47. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S
Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148
[TBL] [Abstract][Full Text] [Related]
48. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
[TBL] [Abstract][Full Text] [Related]
49. [Progress in the treatment of non-Hodgkin's lymphoma (NHL) in children. The report of Polish Pediatric Leukaemia/lymphoma Study Group (PPLLSG)].
Wróbel G; Kazanowska B; Chybicka A; Jeleń M; Małdyk J; Sowińska E; Balcerska A; Balwierz W; Bubała H; Kołakowska-Mrozowska B; Kołtan A; Korzon M; Kowalczyk J; Krawczuk-Rybak M; Maciejka-Kapuścińska L; Matysiak M; Płoszyńska A; Popadiuk S; Solarz E; Sońta-Jakimczyk D; Sopyło B; Stańczak E; Stefaniak J; Stefańska K; Wachowiak J; Wieczorek M; Wysocki M
Przegl Lek; 2004; 61 Suppl 2():45-8. PubMed ID: 15686045
[TBL] [Abstract][Full Text] [Related]
50. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance.
Horn J; Kleber M; Hieke S; Schmitt-Gräff A; Wäsch R; Engelhardt M
Ann Hematol; 2012 Oct; 91(10):1579-86. PubMed ID: 22752146
[TBL] [Abstract][Full Text] [Related]
51. Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry.
Krause SW; Gerken M; Andreesen R; Hofstädter F; Klinkhammer-Schalke M
Ann Hematol; 2012 Apr; 91(4):561-70. PubMed ID: 22200972
[TBL] [Abstract][Full Text] [Related]
52. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
Gerrard M; Cairo MS; Weston C; Auperin A; Pinkerton R; Lambilliote A; Sposto R; McCarthy K; Lacombe MJ; Perkins SL; Patte C;
Br J Haematol; 2008 Jun; 141(6):840-7. PubMed ID: 18371107
[TBL] [Abstract][Full Text] [Related]
53. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
54. Non-Hodgkin lymphoma in children and adolescents.
Reiter A
Klin Padiatr; 2013 May; 225 Suppl 1():S87-93. PubMed ID: 23700066
[TBL] [Abstract][Full Text] [Related]
55. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood.
Fujita N; Kobayashi R; Takimoto T; Nakagawa A; Ueda K; Horibe K
Leuk Lymphoma; 2011 Feb; 52(2):223-9. PubMed ID: 21261497
[TBL] [Abstract][Full Text] [Related]
56. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
57. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
58. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
59. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.
Riihijärvi S; Taskinen M; Jerkeman M; Leppä S
Eur J Haematol; 2011 Feb; 86(2):124-8. PubMed ID: 20942853
[TBL] [Abstract][Full Text] [Related]
60. Prognostic impact of cytogenetic abnormalities in children and adolescents with mature B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Sekimizu M; Mori T; Kikuchi A; Mitsui T; Sunami S; Kobayashi R; Fujita N; Inada H; Takimoto T; Saito AM; Watanabe T; Fujimoto J; Nakazawa A; Ohshima K; Horibe K; Tsurusawa M;
Pediatr Blood Cancer; 2015 Jul; 62(7):1294-6. PubMed ID: 25790170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
